Drug

Low-dose Aldesleukin ILT-101 clinical trials

studies test it: 8
open now: 3
in phase 3: 0
first study started: 2017

Keep track of what changes. Save the Low-dose Aldesleukin ILT-101 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Written with another drug

ILT101: 3
ILT-101 ld-(IL2): 2
ILT-101: 2

Studies by the year they started

8 studies that test it; most in 2019 (2)

Studies that test Low-dose Aldesleukin ILT-101, by start year
Year	Studies
2017	1
2019	2
2020	1
2022	1
2023	1
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 7

What it is tested for

Each study’s main condition, where its own words name it.

Diabetes Mellitus, Type 1: 2
Bipolar Disorder: 1
Lupus Erythematosus, Systemic: 1
Autism Spectrum Disorder: 1

Who runs them

Industry 1 · Other 7

Assistance Publique - Hôpitaux de Paris (6) · Iltoo Pharma (1) · Jay S. Skyler (1)

Often tested with

Tested in the same studies.

Aldesleukin (8)

Studies

Open first, then newest update. How each study uses Low-dose Aldesleukin ILT-101 is read from its arms, and is right about nine times in ten.